Ascites Clinical Trial
Official title:
Utility of 2- Octyl Cyanoacrylate (2-OCA) Skin Adhesive for Prevention of Fluid Leaks Following Therapeutic Paracentesis
Verified date | July 2023 |
Source | Methodist Health System |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Paracentesis is a commonly performed procedure in the inpatient and outpatient settings for treatment of ascites. The most frequent complication of paracentesis is fluid leak. Risk for this complication can be reduced by following the Z-track technique; however, fluid leaks still occur causing significant morbidity. 2-Octyl cyanoacrylate (2-OCA, Dermabond manufactured by Ethicon Inc) skin adhesive has been used for years for skin closure for wounds from surgical incisions including punctures from minimally invasive surgery and simple trauma lacerations.
Status | Enrolling by invitation |
Enrollment | 134 |
Est. completion date | January 13, 2024 |
Est. primary completion date | January 13, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - Inpatients at Methodist Dallas Medical Center (MDMC) =18 years of age with ascites requiring therapeutic paracentesis performed by the procedure team at the bedside. Exclusion Criteria: - Paracentesis procedures performed in the interventional radiology department or by physicians outside of the procedure team. - Patients who undergo a liver transplant surgery or other abdominal surgeries within 48 hours from the paracentesis procedure. - Patients that undergo paracentesis using a device or kit other than the 18 gauge Safe-T-Centesis kit |
Country | Name | City | State |
---|---|---|---|
United States | Methodist Dallas Medical Center Pharmacy | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
Methodist Health System |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Access topical 2-OCA application | To assess if topical 2-OCA application for skin closure would prevent post-paracentesis fluid leaks. | up to 1 year | |
Primary | Access the rate of complications | Assess the rate of complications after topical 2-OCA application post-paracentesis such as skin infections, peritonitis, perforation of viscus, and bleeding. | up to 1 year | |
Primary | Access post-paracentesis fluid leaks | Incidence of post-paracentesis fluid leaks within 48 hours of paracentesis and topical 2-OCA application | up to 1 year | |
Primary | Incidence of bleeding from site | local irritation/burning, infections, and/or perforation within 48 hours post-procedure and topical 2-OCA application. | up to 1 year. | |
Primary | Number of participants with complications from paracentesis procedure | Cellulitis, peritonitis, bleeding, perforated viscus | up to 1 year | |
Primary | Number of participants with Evidence of Skin Reactions | itching, burning, sensation, redness, dermatitis | up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02891642 -
Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid
|
||
Recruiting |
NCT00239096 -
Prevention of Decompensation in Liver Cirrhosis
|
Phase 4 | |
Active, not recruiting |
NCT03973866 -
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
|
N/A | |
Completed |
NCT01349348 -
Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
|
Phase 3 | |
Terminated |
NCT01455246 -
Daptomycin + Meropenem Versus Ceftazidime in the Treatment of Nosocomial Spontaneous Bacterial Peritonitis
|
Phase 2/Phase 3 | |
Completed |
NCT01578226 -
Procalcitonin in Cirrhotic Patients at High Risk for Sepsis
|
N/A | |
Terminated |
NCT00548366 -
Sodium Restriction in the Management of Cirrhotic Ascites
|
Phase 4 | |
Recruiting |
NCT05025878 -
13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.
|
||
Completed |
NCT03327688 -
Point-of-care Ultrasound in Finland
|
N/A | |
Not yet recruiting |
NCT04550091 -
Role Of Multi-detector Computed Tomography In Differentiation Between Different Types Of Ascites
|
||
Completed |
NCT01769040 -
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
|
Phase 4 | |
Not yet recruiting |
NCT01716611 -
Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
|
Phase 4 | |
Recruiting |
NCT05700708 -
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
|
||
Recruiting |
NCT05511766 -
Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis
|
Phase 2/Phase 3 | |
Completed |
NCT05013502 -
Empagliflozin in Diuretic Refractory Ascites
|
Phase 1 | |
Not yet recruiting |
NCT06436807 -
PMCF Study of the CE-marked Drainova® ArgentiC Catheter
|
||
Completed |
NCT03263598 -
Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites
|
||
Completed |
NCT00907673 -
The Automated Fluid Shunt (AFS)in Chronic Congestive Heart Failure
|
N/A | |
Terminated |
NCT00796861 -
Trial of Sunitinib for Refractory Malignant Ascites
|
Phase 2 | |
Suspended |
NCT00511394 -
Acute Hemodynamics of Albumin Versus Normal Saline in Cirrhosis
|
N/A |